Sareum Holdings PLC. Stock Analysis SAR.L

Sareum Holdings Plc engages in the discovery and development of drug candidates for the treatment of cancers and autoimmune diseases. The company is headquartered in Cambridge, Cambridgeshire and currently employs 5 full-time employees. The company went IPO on 2004-10-11. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The firm is focused on advancing inhibitors of the JAK kinase family into clinical development for autoimmune disease and cancer. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development. The firm is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. Additionally, the Company owns the license for SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.